Scott Ripley

Marlborough, Massachusetts, United States
Scott Ripley is the general manager of the nucleic acid therapeutics business for Cytiva, leading the development of products and solutions for nucleic acid based therapies including mRNA. Scott has more than 20 years of experience across research and bioprocess businesses, including a recent focus on the mRNA domain. Previously, Scott has held senior commercial and marketing leadership roles in Cytiva's BioProcessing, Cell Therapy and Research focused businesses. Scott holds a PhD in Plant Sciences from the University of Cambridge, a Bachelors in Botany from the University of Edinburgh, UK and currently resides in Uppsala Sweden. He enjoys amateur astrophotography in his spare time.
Speaking In
11:00 AM - 12:00 PM (PDT)
Tuesday, June 14
Genomic medicines continues to move to the forefront with an expected growth to $95B in 2028 (from …